Transdermal physostigmine-absence of effect on topographic brain mapping.
Nine patients with primary degenerative dementia (PDD) participated in an open trial of transdermal physostigmine (TPh). In order to evaluate the neurophysiologic effects of TPh, EEG data were recorded and compared at baseline and following 2 months of continuous treatment. There was no significant effect of TPh on EEG spectra in patients with PDD.